Role of drug metabolism in drug discovery and development

被引:145
作者
Kumar, GN [1 ]
Surapaneni, S [1 ]
机构
[1] Amgen Inc, Dept Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA
关键词
drug metabolism; drug discovery; cytochrome P450; drug-drug interactions;
D O I
10.1002/med.1016
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Metabolism by the host organism is one of the most important determinants of the pharmacokinetic profile of a drug. High metabolic lability usually leads to poor bioavailability and high clearance. Formation of active or toxic metabolites will have an impact on the pharmacological and toxicological outcomes. There is also potential for drug-drug interactions with coadministered drugs due to inhibition and/or induction of drug metabolism pathways. Hence, optimization of the metabolic liability and drug-drug interaction potential of the new chemical entities are some of the most important steps during the drug discovery process. The rate and site(s) of metabolism of new chemical entities by drug metabolizing enzymes is amenable to modulation by appropriate structural changes. Similarly, the potential for drug-drug interactions can also be minimized by appropriate structural modifications to the drug candidate. However, the optimization of the metabolic stability and drug-drug interaction potential during drug discovery stage has been largely by empirical methods and by trial and error. Recently, a lot of effort has been applied to develop predictive methods to aid the optimization process during drug discovery and development. This article reviews the role of drug metabolism in drug discovery and development. (C) 2001 John Wiley & Sons, Inc.
引用
收藏
页码:397 / 411
页数:15
相关论文
共 39 条
[1]   QUANTITATIVE RELATIONSHIPS BETWEEN STRUCTURE AND MICROSOMAL OXIDATION RATE OF 1,4-DIHYDROPYRIDINES [J].
BAARNHIELM, C ;
WESTERLUND, C .
CHEMICO-BIOLOGICAL INTERACTIONS, 1986, 58 (03) :277-288
[2]   Rifampin drastically reduces plasma concentrations and effects of oral midazolam [J].
Backman, JT ;
Olkkola, KT ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (01) :7-13
[3]   Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].
Bertz, RJ ;
Granneman, GR .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258
[4]   IN-VITRO PROGUANIL ACTIVATION TO CYCLOGUANIL BY HUMAN LIVER-MICROSOMES IS MEDIATED BY CYP3A ISOFORMS AS WELL AS BY S-MEPHENYTOIN HYDROXYLASE [J].
BIRKETT, DJ ;
REES, D ;
ANDERSSON, T ;
GONZALEZ, FJ ;
MINERS, JO ;
VERONESE, ME .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (05) :413-420
[5]   Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6 [J].
Chen, WQ ;
Koenigs, LL ;
Thompson, SJ ;
Peter, RM ;
Pettie, AE ;
Trager, WF ;
Nelson, SD .
CHEMICAL RESEARCH IN TOXICOLOGY, 1998, 11 (04) :295-301
[6]  
Chiba M, 2001, DRUG METAB DISPOS, V29, P1
[7]   FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: Impact on labeling [J].
Davit, B ;
Reynolds, K ;
Yuan, R ;
Ajayi, F ;
Conner, D ;
Fadiran, E ;
Gillespie, B ;
Sahajwalla, C ;
Huang, SM ;
Lesko, LJ .
JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (09) :899-910
[8]   Novel approach to predicting P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for CYP2D6 [J].
de Groot, MJ ;
Ackland, MJ ;
Horne, VA ;
Alex, AA ;
Jones, BC .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (09) :1515-1524
[9]   ROLE OF CYTOCHROME P4501A2 IN CHEMICAL CARCINOGENESIS - IMPLICATIONS FOR HUMAN VARIABILITY IN EXPRESSION AND ENZYME-ACTIVITY [J].
EATON, DL ;
GALLAGHER, EP ;
BAMMLER, TK ;
KUNZE, KL .
PHARMACOGENETICS, 1995, 5 (05) :259-274
[10]   Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR [J].
Greene, N ;
Judson, PN ;
Langowski, JJ ;
Marchant, CA .
SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 1999, 10 (2-3) :299-+